{
    "root": "2dedbadd-050f-4a2e-9425-837bdef7632b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "JAYPIRCA",
    "value": "20250219",
    "ingredients": [
        {
            "name": "pirtobrutinib",
            "code": "JNA39I7ZVB"
        },
        {
            "name": "hypromellose acetate succinate 12070923 (3 MPA.S)",
            "code": "36BGF0E889"
        },
        {
            "name": "microcrystalline cellulose",
            "code": "OP1R32D61U"
        },
        {
            "name": "lactose monohydrate",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "croscarmellose sodium",
            "code": "M28OL1HH48"
        },
        {
            "name": "silicon dioxide",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "magnesium stearate",
            "code": "70097M6I30"
        },
        {
            "name": "hypromellose, unspecified",
            "code": "3NXW29V3WO"
        },
        {
            "name": "titanium dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "triacetin",
            "code": "XHX3C3X673"
        },
        {
            "name": "FD&C BLUE No. 2 Aluminum Lake",
            "code": "4AQJ3LG584"
        }
    ],
    "indications": "jaypirca \u00ae kinase inhibitor indicated treatment adult patients relapsed refractory mantle cell lymphoma ( mcl ) least two lines systemic therapy , including btk inhibitor . ( 1.1 ) . indication approved accelerated approval based response rate . continued approval indication may contingent upon verification description benefit confirmatory trial . adult patients chronic lymphocytic leukemia small lymphocytic lymphoma ( cll/sll ) received least two prior lines therapy , including btk inhibitor bcl-2 inhibitor . ( 1.2 ) . indication approved accelerated approval based response rate . continued approval indication may contingent upon verification description benefit confirmatory trial .",
    "contraindications": "recommended : 200 mg orally daily ; swallow whole water , without food . cut , crush , chew tablets . ( 2.1 ) manage toxicity using treatment interruption , reduction , discontinuation . ( 2.2 ) reduce dose patients severe renal impairment . ( 2.3 , 8.6 )",
    "warningsAndPrecautions": "supplied jaypirca tablets supplied follows : tablet strength description package configuration ndc number 50 mg blue , film coated , arc-triangle shaped tablets debossed \u201c lilly 50 \u201d one side \u201c 6902 \u201d side . bottle child-resistant closure.each bottle contains 30 tablets . 0002-6902-30 100 mg blue , film coated , round tablets debossed \u201c lilly 100 \u201d one side \u201c 7026 \u201d side . bottle child-resistant closure.each bottle contains 60 tablets . 0002-7026-60 storage handling store jaypirca tablets room temperature 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) ( [ usp controlled room temperature ] ) .",
    "adverseReactions": "none .",
    "indications_original": "JAYPIRCA \u00ae is a kinase inhibitor indicated for the treatment of Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. ( 1.1 ). This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. ( 1.2 ). This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",
    "contraindications_original": "Recommended dosage: 200 mg orally once daily; swallow whole with water, with or without food. Do not cut, crush, or chew tablets. ( 2.1 ) Manage toxicity using treatment interruption, dosage reduction, or discontinuation. ( 2.2 ) Reduce dose in patients with severe renal impairment. ( 2.3 , 8.6 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  JAYPIRCA tablets are supplied as follows:\n\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              Tablet Strength\n                           \n                           \n                              Description\n                           \n                           \n                              Package Configuration\n                           \n                           \n                              NDC Number\n                           \n                        \n                        \n                           50 mg\n\n                           Blue, film coated, arc-triangle shaped tablets debossed with \u201cLilly 50\u201d on one side and \u201c6902\u201d on the other side.\n\n                           Bottle with child-resistant closure.Each bottle contains 30 tablets.\n\n                           0002-6902-30\n\n                        \n                        \n                           100 mg\n\n                           Blue, film coated, round tablets debossed with \u201cLilly 100\u201d on one side and \u201c7026\u201d on the other side.\n\n                           Bottle with child-resistant closure.Each bottle contains 60 tablets.\n\n                           0002-7026-60\n\n                        \n                     \n                  \n                  \n                     Storage and Handling\n                  \n                  Store JAYPIRCA tablets at room temperature 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) ([see USP Controlled Room Temperature]).",
    "adverseReactions_original": "None."
}